TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06450054

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise in diabetic post-stroke patients
Description: The experimental group's members will use the treadmill for a five-minute warm-up and cool-down. Over 12 weeks, they will attend three 40-minute weekly sessions in groups of two to four. They will then perform aerobic exercise for thirty minutes at a heart rate reserve of 60% to 80%. Those with a low exercise tolerance will first be given small workouts lasting at least ten minutes, interspersed with rest periods until they can perform 30 minutes of exercise. They will progress to longer, continuous workouts punctuated by shorter rest periods as their tolerance to exercise grows. The degree of treadmill training intensity will be adjusted step-by-step according to each person's tolerance, heart rate, blood pressure responses, and perceived effort rate. If they exercise beyond their cardiovascular conditioning zone, participants will be instructed to raise their treadmill speed until they achieve it

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic Exercise in Non diabetic post-stroke patients
Description: Group B will be managed aerobic exercise in non-diabetic post-stroke patients. Participants in the control group will walk outside comfortably while maintaining a heart rate reserve of less than 40%. They will be instructed to reduce their pace until their training zone reaches ≤40% if their heart rate reserve exceeds 40%. If the efficacy is demonstrated, participants in the control group will receive the experimental intervention
Study: NCT05113888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi weitong granules(High）
Description: take orally before meals, 1 bag each time, 3 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi weitong granules(Low）
Description: take orally before meals, 1 bag each time, 3 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take orally before meals, 1 bag each time, 3 times a day.
Study: NCT06392139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Therapy Program for Personality Disorders
Description: The program was founded in 1999; since then, it has provided a wide range of different treatment interventions (outpatient, inpatient and day care). The interventions are psychoanalytically oriented and specifically for patients with Borderline Personality Disorder. Most of them are in the form of group psychoanalytic psychotherapy. The program consists of two steps: 1) an initial reception outpatient clinic where patients are followed after the referral to the Program, for a period of 6-8 months. This first step consists of monthly psychodynamically oriented sessions, monthly psychiatric appointments and application of psychological assessment instruments. The intervention focuses on crisis management and construction of the treatment plan for every patient. 2) The second step consists of long-term psychodynamic psychotherapy interventions, in combination with psychiatric treatment when it is is needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU) Group
Description: The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital.~Treatment As Usual (TAU) The TAU includes the psychiatric management, consultation and pharmacotherapy if needed in the two Specific Outpatient Clinics for BPD patients. TAU provides one thirty minutes session per month. In case of crisis management patients contact their psychiatrist during the working hours, or after that they leave a message on the telephone answering machine and if needed make a visit in the Emergency Department of the Hospital on Duty.
Study: NCT04736927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: On Day 1 and Day 7 as liquid formulation, orally in fed state.
Study: NCT06144320

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
Study: NCT06498622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib + Envafolimab
Description: Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI
Study: NCT06522555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide
Description: Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanubrutinib, rituximab and lenalidomide
Description: Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Study: NCT04738617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter and intra-individual variation in acute responses to two different warm-up types
Description: Comparison of the acute effects of two different warm-up protocols on subsequent performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter and intra-individual variation in acute responses to two different warm-up types
Description: Comparison of the acute effects of two different warm-up protocols on subsequent performance.
Study: NCT05546216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients
Description: The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
Study: NCT04671043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and glucose
Description: Caffeine and glucose powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose alone
Description: Glucose powder dissolved in water
Study: NCT06141616

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Asthma Rehabilitation Program
Description: The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Rehabilitation Program
Description: The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.
Study: NCT05002894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises for flexibility and stability

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medical standard care for fatigue
Description: supplements and medical care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medical standard care for fatigue
Description: supplements and medical care
Study: NCT05174858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic dressing ETIK COLLAGENE
Description: The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
Study: NCT05179018

Intervention type: DIAGNOSTIC_TEST
Intervention: Ribosomal p2 Autoantibodies as a Serum marker
Description: Using serum marker

Intervention type: DIAGNOSTIC_TEST
Intervention: Ribosomal p2 Autoantibodies as a Serum marker
Description: Using serum marker
Study: NCT06076018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group morphine
Description: Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group placebo
Description: Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
Study: NCT06085443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Hygiene
Description: 2 sprays in each ear, every 3 days at home
Study: NCT05589155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application
Description: Intervention will be with mobile health application
Study: NCT05269875

Intervention type: OTHER
Group type: OTHER
Intervention: ACP
Description: The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
Study: NCT04671043

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Artificial sweetener dissolved in water
Study: NCT06523881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)
Description: Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)
Description: Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
Study: NCT05521334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micropulse transscleral cyclophotocoagulation
Description: glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
Study: NCT05740189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloon 180° Ablation System
Description: The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
Study: NCT04798989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY6463
Description: CY6463 Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study: NCT06043778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community care for People with Schizophrenia in India (COPSI)
Description: This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community care for People with Schizophrenia in India (COPSI)
Description: This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindLAMP Mobile Application
Description: Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
Study: NCT03606538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 80 mg midomafetamine HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 80 mg midomafetamine HCl
Study: NCT06124248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE intervention
Description: The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention.
Study: NCT06597617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted physical activity with aerobic training [GEA]
Description: Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted physical activity with strength training [GRM]
Description: Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity.
Study: NCT06596460

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TAVI planning CT (adapted)
Description: TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
Study: NCT06648876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: 10mg qd for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: 10mg qd for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: 10mg qd for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg qd for 8 days
Study: NCT06658405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.
Study: NCT06665425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epaminurad 9 mg
Description: Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2406
Description: Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Study: NCT06667154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose nivolumab combined with platinum-based doublet chemotherapy
Description: Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
Study: NCT06667999

Intervention type: DRUG
Group type: OTHER
Intervention: Albumin
Description: Albumin should be used for the following indications: 1. During circulatory failure in addition to crystalloids (resuscitation). 2. For substitution in case of: suspected or overt albumin loss OR P-albumin levels below or equal to 25 g/L. Decisions around timing, volume, and concentration of albumin, and its use for other indications, are at the clinician's discretion. P-albumin should be measured according to local practice.

Intervention type: OTHER
Group type: OTHER
Intervention: No albumin
Description: Albumin should not be used. In case of the following special circumstances, albumin may be considered: 1. Large ascites drainage (i.e., equal to or more than 1 L tapped) 2. Spontaneous bacterial peritonitis 3. Hepatorenal syndrome.
Study: NCT06668493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: Repeat dose trial to investigate the safety and efficacy of nadofaragene firadenovec instilled into the renal pelvis
Study: NCT05854303

Intervention type: BEHAVIORAL
Intervention: Opioid cessation
Description: opioid cessation will occur during pain rehabilitative program over approximately 3 weeks

Intervention type: OTHER
Intervention: No opioid cessation
Description: Subjects will not stop taking opioids
Study: NCT05911828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZY19489 + Ferroquine (FQ)
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
Study: NCT04641962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral